In this CME activity, Review the latest advancements in human epidermal growth factor receptor 2 (HER2)-ultralow mBC by joining this in-depth discussion between leading pathology and medical oncology experts. Learn how a new drug indication as well as updated ASCO/CAP guidelines for HER2-low and -ultralow classifications will redefine the way patients with HER2 mBC are both diagnosed and treated.
Educational Provider
This activity is provided by USF Health in partnership with Paradigm Medical Communications, LLC and Moffitt Cancer Center.
Supporter Acknowledgment
This activity is funded by independent medical education grants from Daiichi Sankyo, Inc and AstraZeneca.
